- Aardvark Therapeutics is developing **ARD-101**, an oral, gut-restricted small molecule drug designed to activate taste receptors in the small intestine, triggering the release of gut peptide hormones to dampen appetite and hunger for conditions such as Prader-Willi syndrome and general obesity.  **[1774857_2162306_0]** 
- In a Phase 2 study for Prader-Willi syndrome, ARD-101 showed encouraging results over a **28-day treatment period**, with HQ-CT9 scores demonstrating an **almost 50% reduction** from baseline and an average **1.5% reduction in body fat percentage**.  **[1774857_2162306_3]** 
- The company's Phase 3 trial for ARD-101 in Prader-Willi syndrome has expanded age inclusion to **13 and up** and is powered with **45 patients per arm**; an interim assessment for sample size re-estimation is anticipated around **Obesity Week (first week of November)** or the Q3 update.  **[1774857_2162306_5]** 
- Aardvark is also advancing **ARD-201**, a fixed-dose combination of ARD-101 and sitagliptin, which achieved **19% weight loss** in a diet-induced obese mouse model, comparable to tirzepatide, and a microdose of tirzepatide combined with ARD-201 showed **30% weight reduction** in the same model.  **[1774857_2162306_6]**

Aardvark Therapeutics (AARD)